TRCT
SABSW icon

Tower Research Capital (TRC)’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Tower Research Capital (TRC)’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-48
Closed -$4 – 5701
2024
Q4 		$4 Hold
48
– – ﹤0.01% 5640
2024
Q3 		$2 Hold
48
– – ﹤0.01% 5665
2024
Q2 		$2 Hold
48
– – ﹤0.01% 5638
2024
Q1 		$2 Hold
48
– – ﹤0.01% 5814
2023
Q4 		$1 Hold
48
– – ﹤0.01% 5894
2023
Q3 		$4 Hold
48
– – ﹤0.01% 5889
2023
Q2 		$5 Hold
48
– – ﹤0.01% 5976
2023
Q1 		$0 Hold
48
– – ﹤0.01% 6216
2022
Q4 		$0 Hold
48
– – ﹤0.01% 6305
2022
Q3 		$0 Hold
48
– – ﹤0.01% 6424
2022
Q2 		$0 Hold
48
– – ﹤0.01% 6464
2022
Q1 		$0 Hold
48
– – ﹤0.01% 6488
2021
Q4 		$0 Buy
+48
New +$88 ﹤0.01% 6519

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Tower Research Capital (TRC)'s SABSW Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of SAB Biotherapeutics Warrant (SABSW) in Q1 2025, closing a stake of 48 shares — an estimated $4 sold.

Tower Research Capital (TRC) first reported a position in SABSW in Q4 2021 and held it in 13 quarters. The position peaked at $5 in Q2 2023. 7 funds tracked by Wall St. Rank hold SABSW as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining SAB Biotherapeutics Warrant position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 48 SAB Biotherapeutics Warrant shares in Q1 2025, an estimated $4.
  • Tower Research Capital (TRC) first reported a position in SAB Biotherapeutics Warrant in Q4 2021 and held it in 13 quarters.
  • Tower Research Capital (TRC)'s SAB Biotherapeutics Warrant position peaked at $5 in Q2 2023.
  • 7 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.